Dow Agrosciences Llc v. The Controller Of Patents

In the world of agricultural biotechnology, a single patent can be the difference between market dominance and being left behind. When the patent office says no to a method that could transform how cotton genetics are tested, the fight moves to the courts — and sometimes, the courts themselves change mid-fight. This is the story of how one company's pursuit of patent protection for a specialized genetic testing method became a test of both innovation and jurisdiction.

Dow Agrosciences LLC, a prominent name in agricultural sciences, filed a patent application titled 'ENDPOINT TAQMAN METHODS FOR DETERMINING ZYGOSITY OF COTTON.' The application sought to protect a method related to determining the zygosity of cotton plants — a critical process in plant genetics and breeding. However, on September 9, 2020, the Controller of Patents issued a rejection order against the application, refusing to grant the patent. Aggrieved by this decision, Dow Agrosciences filed an appeal to challenge the rejection. The case was originally destined for the Intellectual Property Appellate Board (IPAB), but with the enactment of the Tribunals Reforms Act, 2021, the IPAB was dissolved and its pending matters were transferred to the Delhi High Court. The appeal thus came up before the Delhi High Court, listed for hearing on September 27, 2022.

Dow Agrosciences LLC, as the appellant, challenged the rejection order of the Controller of Patents, arguing that its invention — an endpoint TaqMan method for determining zygosity in cotton — deserved patent protection. The Controller of Patents, as the respondent, had maintained that the application did not meet the requirements for patentability under the relevant provisions of the Patents Act. The core legal friction centered on whether the method described in the application qualified as a patentable invention, particularly in light of the standards for novelty, inventive step, and industrial application. The procedural dimension added another layer of complexity: the case had to be heard in a new forum after the abolition of the IPAB, raising questions about continuity and the proper adjudication of intellectual property appeals.

As of the listing date of September 27, 2022, the matter remained pending before the Delhi High Court. The court had not yet issued a final ruling on the merits of the appeal, and the specific legal reasoning and statutory provisions to be applied were yet to be determined. The case stands as an example of how patent disputes can be prolonged by institutional transitions, leaving innovators in limbo while awaiting clarity on the protectability of their inventions.

For founders and IP professionals in the biotech and agricultural sectors, this case underscores the importance of preparing patent applications with meticulous attention to the statutory requirements for patentability — particularly novelty and inventive step. When a patent is rejected, the appeals process can be lengthy, especially when jurisdictional changes are involved. Startups and innovators should build contingency timelines into their IP strategies, anticipate potential forum shifts, and ensure that their patent specifications are drafted with enough technical depth and clarity to withstand scrutiny at both the examination and appellate stages.